Drug intelligence / Profile preview

HArmonyCa + lidocaine

Development stage
Unknown
Lead developer
Allergan Aesthetics
Modality
Small Molecules
Administration
Subdermal, Deep Dermal, Subcutaneous (facial Injection)
01

Overview

HArmonyCa + lidocaine is a hybrid injectable dermal filler combining cross-linked hyaluronic acid and calcium hydroxyapatite (CaHA) microspheres, formulated for facial soft tissue augmentation, particularly aimed at lifting, volumizing, and rejuvenating the mid and lower face[1][3][4][5][6]. The formulation contains 0.3% lidocaine hydrochloride to minimize pain during injection[1][3][4][5]. Hyaluronic acid provides immediate lifting and hydrating effects, while the CaHA microspheres serve as a biostimulator that progressively stimulates endogenous collagen production for long-term skin tightening and structural support, helping to remodel skin and ameliorate signs of facial aging[1][4][5]. The dual-action mechanism delivers both instant and sustained improvements, making it appropriate for volume loss, lack of firmness, and contouring in facial aesthetic procedures[1][3][4][5]. The product is contraindicated in cases of severe allergies, bleeding disorders, or autoimmune disease, and is intended for adult use in subdermal and deep dermal facial layers[1][3][4][6]. Developed by Allergan Aesthetics, now part of AbbVie[1][4][5][6].

Brand names
HArmonyCa LidocaineHArmonyCa with lidocaine
Other names
HarmonyCaHarmonyCa Lidocaine
02

Targets

SCN9A (Sodium channel protein type 9 subunit alpha)

Beyond the preview

Go deeper on HArmonyCa + lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HArmonyCa + lidocaine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call